Showing results (581-590 of 604) with videos related to

Sort By:
Pageof 61
The Journal of Clinical Investigation|June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignanciesJustin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 5, 2024
Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosisHung N Nguyen, Yunju Jeong, Yunhye Kim, et al.
Nature Medicine|October 22, 2021
IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapiesMatthias Friedrich, Mathilde Pohin, Matthew A Jackson, et al.
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Emerging Infectious Diseases|June 18, 2004
Endemic Venezuelan equine encephalitis in northern PeruPatricia V Aguilar, Ivorlyne P Greene, Lark L Coffey, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Leukemia Research|July 12, 2025
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndromeJames M Foran, Guillermo F Sanz, Justin M Watts, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I TrialNaseema Gangat, Christian Marinaccio, Ronan Swords, et al.
Med (New York, N.Y.)|June 1, 2022
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseasesIlya Korsunsky, Kevin Wei, Mathilde Pohin, et al.
Pageof 61